Regulatory Health Canada approves Biocon’s two denosumab biosimilars Pharmaceutical TechnologyBiocon has received a Notice of Compliance from Health Canada for Bosaya and Vevzuo, both biosimilars referencing Prolia and Xgeva, respectively.RegulatoryRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaceutical Technology Biocon has received a Notice of Compliance from Health Canada for Bosaya and Vevzuo, both biosimilars referencing Prolia and Xgeva, respectively. RegulatoryRead full story Post navigation Previous: Tortugas debuts with $106M and brain drugs from Hansoh, EisaiNext: Medicare obesity drug pilot extended after insurer pushback Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026